Peter Franz Riederer (Konigsberg, Germany, 1942) holds bachelor’s and doctorate degrees in Science from the Technical University (TU) of Vienna. Since 1986, he has served as Chief of Neurochemistry at the Psychiatry and Psychotherapy Polyclinic of the Medical School of Wurzburg, Germany. Prior to that (1971-1986), he served as Chief of Clinical Neurochemistry at the Ludwig Boltzmann Institute (Lainz Hospital) in Vienna.
His principal scientific interest has been in research projects within the field of neuropsychiatry, particularly involving the use of selegiline in the treatment of Parkinson’s disease.
Peter Franz Riederer has served as President of the German Association of Biological Psychiatry DGBP) (1994-1998), President of the European Association for Clinical Neuropharmacology ESCNP) (1995-96), and President of the German Parkinson’s Association (DPG) (2000-2004).
He has also presided over the Organisation of the International Biological Psychiatry Conference (Berlin, 2001), the 16th International Symposium on Parkinson’s Disease (Berlin, 2005), the 39th International Danubian Symposium on Neuroscience (Wurzburg, 2007), and the 1st International Conference on Attention Deficit/Hyperactivity Disorder (ADHD) (Wurzburg, 2007).
Riederer has received 14 international awards and is an Honorary Member of 15 scientific associations. He has coordinated numerous symposiums, workshops and conferences, and has published around 950 scientific writings and a total of 20 books in the fields of neurology and psychiatry.
He also serves as Head of the Brain Bank Centre in Wurzburg and is active in the BrainNet Europe II initiative.